BIOTECH ASSISTANT / FIELD NOTES

Sanofi ends SAR448272 STAT6 degrader program, Nurix says

Company / institutional announcement · Nurix Therapeutics

Source published: 2026-11-03

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Nurix said Sanofi will stop the first-in-human Phase 1 trial of oral STAT6 degrader SAR448272 and end the program. Nurix no longer expects future milestone payments or royalties from this asset, while other licensed programs remain eligible for such payments. The November 3 announcement did not disclose the reason for discontinuation.

Why it may matter

Potential business implications: The termination highlights early-stage development and partnering risks, without establishing a class-wide setback for STAT6 degraders.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Protein degradation / PROTAC

Follow the evidence

Companies mentionedSanofi ↗

Explore field companies →Explore literature →

Related updates

2026-11-06Nature Materials

In situ CAR engineering and nanoparticle-mediated TREM2 degradation for macrophage reprogramming in malignant ascites

A Nature Materials study describes mRNA-loaded LNPs that reprogram tumor-associated macrophages into Claudin18.2-targeting CAR macrophages. The lipid formulation also promotes TREM2 internalization and degradation, reshaping immune responses. The original abstract reports tumor suppression and longer survival with PD-1 blockade in mice, plus ex vivo patient-sample findings. These findings do not demonstrate clinical efficacy in treated patients.

mRNA / LNP In Vivo Cell Engineering & Gene Editing Protein degradation / PROTAC Ask AI ↗

2026-11-06Frontiers in Pharmacology

Review assesses the safety limits and translational gaps of MCL-1 degradation strategies

A Frontiers in Pharmacology review compares direct MCL-1 inhibition with approaches that reduce its abundance, including transcriptional interventions and targeted degradation. The original abstract highlights limited single-agent activity and cardiac safety concerns with inhibitors, while positioning degradation as an unvalidated clinical strategy. Biomarker-guided combinations and dynamic BH3 profiling are discussed; this review does not report a new clinical trial.

Protein degradation / PROTAC Ask AI ↗

2026-11-05C4 Therapeutics (GlobeNewswire)

C4 completes first cemsidomide–elranatamab safety-cohort enrollment and updates Phase 2 timeline

C4 Therapeutics reported completed enrollment of the first safety cohort in its Phase 1b cemsidomide–elranatamab combination trial. It expects Phase 2 MOMENTUM enrollment to finish in the first quarter of 2027, with initial response-rate data in the second half. At September 30, cash, cash equivalents and marketable securities totaled $274.7 million, with projected runway through 2028.

Companies mentionedC4 Therapeutics ↗

Protein degradation / PROTAC Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗